Want to see NUVB full AI Analyst Report?
NUVB Stock Chart & Stats
$6.42
-$0.07(-1.08%)
At close: 4:00 PM EDT
$6.42
-$0.07(-1.08%)
Day’s Range― - ―
52-Week Range$2.18 - $9.75
Previous CloseN/A
Volume6.14M
Average Volume (3M)8.03M
Market Cap
$2.33B
Enterprise Value$1.30K
Total Cash (Recent Filing)$533.73M
Total Debt (Recent Filing)$9.83M
Price to Earnings (P/E)―
Beta1.62
Next Earnings
Aug 06, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.42
Shares Outstanding348,201,970
10 Day Avg. Volume6,156,846
30 Day Avg. Volume8,034,544
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)10.01
Price to Sales (P/S)48.65
P/FCF Ratio-17.61
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$15.00Price Target Upside133.64% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.35
Revenue Forecast (FY)$201.03M
Bulls Say, Bears Say
Bulls Say
Strong Revenue Growth With High Gross MarginRevenue surged ~127% to $143M on a TTM basis while gross margin remained very high (~91.6%), showing scalable unit economics and durable commercial traction. High gross margins provide structural leverage to translate sales into sustainable profitability if operating losses moderate.
Differentiated Clinical Efficacy And Guideline InclusionRobust clinical durability (≈50 month DOR/PFS in TKI‑naive) and strong CNS responses backed inclusion in NCCN CNS guidelines. These durable clinical advantages support long-term prescribing preference, reimbursement positioning, and competitive moat in ROS1 NSCLC across treatment lines.
Healthy Liquidity And Capital Structure ActionsA cash balance of ~$534M plus $50M undrawn term loan and recent convertible note financing extend runway and reduce immediate refinancing risk. Replacing secured debt and adding long‑dated convertibles improves near‑term flexibility to fund launches and trials without urgent external equity raises.
Bears Say
Sustained Negative Cash Flow And BurnPersistent operating cash outflows (~-$126M TTM) and declining free cash flow growth signal structural cash burn to fund commercialization and R&D. Without conversion of top‑line momentum into positive operating cash flow, the company will remain dependent on financing, pressuring long‑term self‑funding.
Reliance On Collaboration/upfront Milestone RevenueA meaningful portion of recent revenue derived from a large Eisai upfront; such milestone and upfront payments are contingent and timing‑dependent. Dependence on partnership milestones creates revenue volatility and can mask underlying commercial sustainability if product sales don't scale.
Plateaued New Patient Starts And Testing GapsNew patient starts have been steady at ~200/quarter for multiple quarters and community RNA testing is low in parts of the market, capping addressable detection. These structural adoption constraints could limit organic growth unless diagnostic uptake meaningfully improves.
Nuvation Bio News
NUVB FAQ
What was Nuvation Bio Inc’s price range in the past 12 months?
Nuvation Bio Inc lowest stock price was $2.18 and its highest was $9.75 in the past 12 months.
What is Nuvation Bio Inc’s market cap?
Nuvation Bio Inc’s market cap is $2.33B.
When is Nuvation Bio Inc’s upcoming earnings report date?
Nuvation Bio Inc’s upcoming earnings report date is Aug 06, 2026 which is in 8 days.
How were Nuvation Bio Inc’s earnings last quarter?
Nuvation Bio Inc released its earnings results on May 04, 2026. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of -$0.028 by $0.038.
Is Nuvation Bio Inc overvalued?
According to Wall Street analysts Nuvation Bio Inc’s price is currently Undervalued.
Does Nuvation Bio Inc pay dividends?
Nuvation Bio Inc does not currently pay dividends.
What is Nuvation Bio Inc’s EPS estimate?
Nuvation Bio Inc’s EPS estimate is -0.14.
How many shares outstanding does Nuvation Bio Inc have?
Nuvation Bio Inc has 348,201,970 shares outstanding.
What happened to Nuvation Bio Inc’s price movement after its last earnings report?
Nuvation Bio Inc reported an EPS of $0.01 in its last earnings report, beating expectations of -$0.028. Following the earnings report the stock price went up 9.524%.
Which hedge fund is a major shareholder of Nuvation Bio Inc?
Currently, no hedge funds are holding shares in NUVB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nuvation Bio Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.00 (133.64% Upside)
$15.00 (133.64% Upside)
Blogger Sentiment
Bullish
NUVB Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 2.2M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $118.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.8%
Last 30 Days ▲ 17.9%
Last 30 Days ▲ 17.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
155.77%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
23.91%
Trailing 12-Months
Company Description
Nuvation Bio Inc
Nuvation Bio Inc. (NUVB) is a clinical-stage biopharmaceutical company focused on developing targeted cancer therapies. The company’s pipeline consists of investigational oncology drug candidates intended to treat genetically defined or otherwise biomarker-selected patient populations, including small-molecule and antibody-based approaches being evaluated in clinical and preclinical programs.
NUVB Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial and clinical momentum for Iptrozy: robust physician awareness (97%), growing first‑line mix (>50% of new starts), meaningful sequential product revenue growth (18% QoQ to $18.5M), and differentiated durability and CNS efficacy (50‑month PFS/DOR in TKI‑naive; 66% intracranial RR). Financially, the quarter was bolstered by a near‑term collaboration upfront (~$60M) and a healthy cash position ($533.7M) with $50M credit available. Key challenges include a steady absolute level of new patient starts (~200/quarter), testing shortfalls in the community (<50% in some centers) that limit incidence capture, upward pressure on gross‑to‑net (targeting stabilization in the high‑20s to ~30%), and sizeable operating expenses ($73.5M). Overall, positive clinical differentiation, market access progress, partnerships, and balance sheet strength outweigh the operational and market access headwinds.View all NUVB earnings summariesNUVB Stock 12 Month Forecast
Average Price Target
$15.00
▲(133.64% Upside)
Technical Analysis
Nektar Therapeutics
―
Precigen
―
Wave Life Sciences
―
Enliven Therapeutics
―
Praxis Precision Medicines
―
Ownership Overview
24.85% Insiders
15.76% Mutual Funds
0.37% Other Institutional Investors
47.89% Public Companies and Individual Investors